GUTS Stock Analysis: Buy, Sell, or Hold?
GUTS - Fractyl Health, Inc. Common Stock
$0.68
-0.01 (-1.14%)
▼
5d:
-15.46%
30d:
-11.13%
90d:
-3.16%
HOLD
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 11, 2026
6d
Get Alerted When GUTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: GUTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: GUTS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: GUTS is currently trading at $0.68, which is considered oversold relative to its 30-day fair value range of $0.73 to $0.83.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GUTS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.03 (+643.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, GUTS is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GUTS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $5.03 (+643.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.73 -
$0.83
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 643.3% below Wall St target ($5.03)
- CAUTION: 5-day price weakness (-15.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.73 -
$0.83
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.67
Resistance Level
$0.82
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.98
Wall Street Target
$5.03
(+643.3%)
Revenue Growth (YoY)
-57.1%
Share & Embed Analysis
Last updated: August 04, 2026 9:32 AM ET
Data refreshes hourly during market hours. Next update: 10:32 AM
Data refreshes hourly during market hours. Next update: 10:32 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GUTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
